ArticleBiotechnology and bioengineering2009
Generic plasmid DNA production platform incorporating low metabolic burden seed-stock and fed-batch fermentation processes.
Article in Biotechnology and bioengineering, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- From Bioreactor to Bulk Rheology: Achieving Scalable Production of Highly Concentrated Circular DNA.Advanced materials (Deerfield Beach, Fla.) · 2024Article
- Increasing the Pentose Phosphate Pathway Flux to Improve Plasmid DNA Production in EngineeredMicroorganisms · 2024Article
- Expression and purification of fluorinated proteins from mammalian suspension culture.Methods in enzymology · 2024Article
- Sulfate limitation increases specific plasmid DNA yield and productivity in E. coli fed-batch processes.Microbial cell factories · 2023Article
- Article
- Article
- Non-Clinical In Vitro Evaluation of Antibiotic Resistance Gene-Free Plasmids Encoding Human or Murine IL-12 Intended for First-in-Human Clinical Study.Pharmaceutics · 2021Article
- To Plate or to Simply Unfreeze, That Is the Question for Optimal Plasmid Extraction.Journal of biomolecular techniques : JBT · 2021Article
- Plasmid DNA Production in Proteome-ReducedMicroorganisms · 2020Article
- Application of Plasmid Engineering to Enhance Yield and Quality of Plasmid for Vaccine and Gene Therapy.Bioengineering (Basel, Switzerland) · 2019Article
- Optimization of fermentation conditions for anJournal of biological engineering · 2018Article
- Effect of plasmid replication deregulation via inc mutations on E. coli proteome & simple flux model analysis.Microbial cell factories · 2015Article
- Increasing plasmid-based DNA vaccine construct (16 kb pSVK-HBVA) production inBiotechnology, biotechnological equipment · 2015Article
- Antibiotic-free production of a herpes simplex virus 2 DNA vaccine in a high yield cGMP process.Human vaccines & immunotherapeutics · 2013Article
- Review
- Development of new plasmid DNA vaccine vectors with R1-based replicons.Microbial cell factories · 2012Article
- Improved antibiotic-free plasmid vector design by incorporation of transient expression enhancers.Gene therapy · 2011Article
- Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine.Journal of virology · 2011Article
- Vector insert-targeted integrative antisense expression system for plasmid stabilization.Molecular biotechnology · 2011Article
- Critical design criteria for minimal antibiotic-free plasmid vectors necessary to combine robust RNA Pol II and Pol III-mediated eukaryotic expression with high bacterial production yields.The journal of gene medicine · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
DNA vaccines have tremendous potential for rapid deployment in pandemic applications, wherein a new antigen is "plugged" into a validated vector, and rapidly produced in a validated, fermentation-purification process. For this application, it is essential that the vector and fermentation process function with a variety of different antigen genes. However, many antigen genes are unpredictably "toxic" or otherwise low yielding in standard fermentation processes. We report cell bank and fermentation process unit operation innovations that reduce plasmid-mediated metabolic burden, enabling successful production of previously known toxic influenza hemagglutinin antigen genes. These processes, combined with vector backbone modifications, doubled fermentation productivity compared to existing high copy vectors, such as pVAX1 and gWiz, resulting in high plasmid yields (up to 2,220 mg/L, 5% of total dry cell weight) even with previously identified toxic or poor producing inserts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.